Adrafinil

• 5 grams powder
• Dry-fill capsules (50 mg per capsule, 60-count / 3 g total)
• 30 mL liquid solution (50 mg per mL / 1.5 g total)

Research indicates Adrafinil may exert its effects through wakefulness-promoting pathways rather than direct stimulant action: Because of its prodrug nature, Adrafinil typically demonstrates a slower onset and longer duration than direct eugeroics.

• Metabolized into modafinil through hepatic pathways
• Enhances orexin, also known as hypocretin, signaling
• Modulates dopamine-transporter activity without strongly promoting dopamine release
• Increases histaminergic and adrenergic tone
• Promotes sustained alertness without classic sympathomimetic overstimulation

Adrafinil is commonly studied in

• Wakefulness and vigilance research
• Fatigue-resistance and endurance models
• Sleep-deprivation and circadian-disruption studies
• Cognitive performance under prolonged task demands
• Shift-work and sustained-attention models

Reported or historically noted findings include: Due to its hepatic metabolism, Adrafinil is frequently studied with attention to liver-function markers in longer-term research designs.

• Headache
• Nausea or gastrointestinal discomfort
• Insomnia when administered late in the wake cycle
• Elevated liver-enzyme markers with repeated high-dose exposure
• Mild anxiety or restlessness in sensitive models

Researchers generally avoid combining Adrafinil with other hepatically taxing agents when studying longer-duration exposure models.